About

2D Biologics: Redefining the Future of Cancer Treatment

Co-founded by Dr. Primal de Lanerolle and David Downs, MBA, 2D Biologics is a pioneering pharmaceutical startup at the cutting edge of cancer therapeutics. We are developing a first-in-class cancer drug that targets a structural vulnerability common to over 85% of solid tumors—including prostate and breast cancers—regardless of genetic profile.

Breakthrough Discovery:
In preclinical studies, our drug has demonstrated powerful tumor-killing effects with no significant short-term side effects and has shown synergistic potential with existing cancer therapies, amplifying their effectiveness. This platform approach could unlock a new standard of care across a wide range of solid tumors. 

Cost-Effective:

Our drug is a small molecule that will be cheaper to produce and use than most genetic approaches to treating cancer. When our treatment is used in combination with standard chemotherapeutic agents or potentially with other cancer treatments can enable lower dosing, improve therapeutic outcomes, and significantly reduce treatment costs. This cost efficiency could be especially impactful in developing regions, where access to affordable cancer therapies remains a major challenge. 

Strategic Vision:
We are currently focused on building strategic partnerships to accelerate development. 

Discover how 2D Biologics is redefining cancer treatment: 🔗 About 2D Biologics